GRNA - GreenLight Biosciences  GAAP EPS of -$0.26 beats by $0.03 revenue of $3.02M beats by $1.42M

2023-03-28 17:14:42 ET

• GreenLight Biosciences press release ( NASDAQ: GRNA ): Q4 GAAP EPS of -$0.26 beats by $0.03 .
• Revenue of $3.02M (+619.0% Y/Y) beats by $1.42M .
• Cash, cash equivalents, and marketable securities were $68.1 million as of December 31, 2022, compared to $31.4 million as of December 31, 2021.
• The Company expects its cash and equivalents of $68.1 million as of December 31, 2022 will be sufficient to fund planned operating expenses and capital expenditures, through the second quarter of 2023.

For further details see: